No video visit
All states
GLP-1 weight loss in Vermont
- Visit type
- No video visit required
- Licensing
- Vermont Board of Medical Practice
- Updated
- Licensed by
- Vermont Board of Medical Practice
- Telehealth
- No video visit required
- Semaglutide injections
- Available
- Tirzepatide injections
- Available
- Medicaid
- Limited coverage
- Shipping
- 2–3 business days
Vermont residents can now access GLP-1 medications like semaglutide and tirzepatide through telehealth — from Burlington and Montpelier to Rutland, Brattleboro, and the smallest Green Mountain town. Pallas Health connects you with a board-certified provider licensed in Vermont who can evaluate your eligibility in under 5 minutes and, if appropriate, prescribe medication that ships to any Vermont address in a few business days.
How telehealth prescribing works in Vermont
Vermont permits licensed providers to establish a patient relationship and prescribe non-controlled medications like GLP-1s through telehealth, including synchronous video and store-and-forward (asynchronous) review. Under 18 V.S.A. § 9361(b) and the Board of Medical Practice telemedicine policy, prescribing via telemedicine is at the provider's professional discretion provided the standard of care is met.
Vermont permits telemedicine broadly under 18 V.S.A. § 9361(b) and the Vermont Board of Medical Practice Policy on Telemedicine. A health care provider licensed in Vermont may prescribe medications to a patient after performing an appropriate examination in person, through telemedicine, or by the use of instrumentation and diagnostic equipment through which images and medical records may be transmitted electronically. Vermont law explicitly recognizes store-and-forward (asynchronous) telehealth, defined as an asynchronous transmission of medical information reviewed at a later date by a provider at a distant site. Prescribing via telemedicine is at the provider's professional discretion, carrying the same professional accountability as in-person prescriptions. Vermont also requires telemedicine providers to post licensure or identifying information about their providers publicly (Vermont Board of Medical Practice Policy on Telemedicine). Pallas publishes its clinical partners (Lion MD and CareValidate), provider leadership, and NPI numbers — with direct links to the federal NPPES NPI Registry — on our clinical disclosures page at pallashealth.co/clinical, where the full prescribing roster's licensure can be verified. Vermont participates in the Interstate Medical Licensure Compact (IMLC), which streamlines licensing for qualifying out-of-state providers. Every Pallas clinician who treats Vermont patients holds an active Vermont license or a qualifying compact license. GLP-1s are not controlled substances, so Vermont's separate Prescription Monitoring System requirements don't add friction here, but our providers still document a complete history, screen for contraindications like personal or family history of medullary thyroid carcinoma, and schedule follow-up visits to monitor response and titrate the dose.
Medicaid & insurance in Vermont
Vermont Medicaid covers GLP-1 agonists including Wegovy for clinically appropriate needs. However, the Vermont Medicaid State Plan has historically excluded weight-loss-only indications, and coverage may require documented medical necessity beyond obesity alone (e.g. type 2 diabetes, cardiovascular risk). Compounded GLP-1s are not covered. Pallas is a cash-pay service, so Medicaid rules do not affect our pricing. Pallas is a cash-pay telehealth service. Medicaid and private insurance do not apply to our prescriptions; pricing is flat and disclosed up front.
Simple cash-pay pricing in Vermont
No insurance, and the same price in every Vermont ZIP code. You see your full price during intake, before you pay anything. One plan price covers your US-licensed provider, check-ins, dose adjustments and care-team messaging, with no membership fee. Medication ships free, and nothing is charged until a clinician prescribes. Cancel anytime. Your clinician helps determine which option is appropriate for you.
Compounded
- Semaglutide injectionsFrom $139
- Tirzepatide injectionsFrom $179
Brand-name
- Wegovy® injectionsFrom $499
- Zepbound® injectionsFrom $499
- Ozempic® injectionsFrom $499
- Mounjaro® injections$1,099/mo
- Wegovy® pillFrom $299
- Foundayo™ pillFrom $299
Semaglutide vs tirzepatide in Vermont
Both are once-weekly injections available to Vermont patients through Pallas, as compounded preparations and as the FDA-approved brand-name products. They work differently: semaglutide activates the GLP-1 receptor, while tirzepatide activates both the GLP-1 and GIP receptors — two of the gut hormones that regulate appetite and fullness.
In SURMOUNT-5, the head-to-head clinical trial of the FDA-approved products, Zepbound® (tirzepatide 10 mg or 15 mg weekly) produced greater average weight loss than Wegovy® (semaglutide 1.7 mg or 2.4 mg weekly) — 20.2% versus 13.7% of body weight over 72 weeks — with broadly similar tolerability. That trial predates Wegovy®'s higher 7.2 mg weekly dose, which reached 18.7% average weight loss over 72 weeks in the separate STEP UP trial; separate trials do not provide a direct comparison. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary.
Cost and track record differ too: compounded semaglutide renews at $199 every 4 weeks versus $299 for tirzepatide (full terms in the questions below), and semaglutide has the longer post-market record. Which medication fits your health history, goals, and budget is a decision you make with a clinician licensed in Vermont — our full semaglutide vs tirzepatide comparison covers the deeper differences.
Cities served in Vermont
Partner pharmacies ship to every ZIP code in Vermont, including:
- Burlington
- Essex
- South Burlington
- Rutland
- Barre
Vermont GLP-1 questions
Start the online intake (about 5 minutes). A Vermont-licensed clinician reviews it by secure message, and if a GLP-1 is appropriate, a US-licensed pharmacy ships it to you in 2–3 business days.
Same intake as semaglutide. If appropriate, a Vermont-licensed clinician can prescribe compounded tirzepatide or FDA-approved Zepbound® or Mounjaro®, and explains which fits you.
Yes. A Vermont-licensed clinician can prescribe it for you with a documented clinical reason, and a US-licensed compounding pharmacy prepares it per patient. Brand-name Wegovy® is also available.
Yes. Vermont nurse practitioners prescribe independently, with no physician agreement required. GLP-1s are not controlled substances, so they can be prescribed by telehealth.
Several do. Check that its clinicians are licensed in Vermont, that it uses US-licensed compounding pharmacies, and that it is LegitScript-certified. Pallas serves Vermont.
No. Vermont allows a licensed clinician to review your intake by secure message and prescribe without a scheduled video call. They may ask for a video visit only if your history calls for it.
Vermont Medicaid covers GLP-1 agonists including Wegovy for clinically appropriate needs. Compounded GLP-1s are not covered. Pallas is cash-pay, so Medicaid rules do not apply.
Yes. Vermont requires telemedicine providers to disclose licensure publicly. Pallas lists its clinical partners, medical leadership and their NPI numbers at pallashealth.co/clinical.
Most Vermont patients receive their medication within 2–3 business days of the pharmacy filling the prescription. Burlington and Essex ship fastest; rural ZIP codes may take an extra day.
Yes. Under federal law (FDCA §503A) a licensed pharmacy may compound semaglutide for an individual patient from a valid prescription. Pallas works only with US-licensed compounding pharmacies.
One flat cash-pay price, the same in every Vermont ZIP code, no insurance needed. It covers your clinician, check-ins and messaging, and medication ships free once prescribed.
A Vermont-licensed clinician decides after reviewing your intake. GLP-1s are generally considered at a BMI of 30 or more, or 27 or more with a condition like high blood pressure.
Wegovy®, Ozempic®, Zepbound® and Mounjaro® are FDA-approved. Compounded semaglutide and tirzepatide are made per patient by US-licensed pharmacies and are not FDA-approved. Your clinician decides.
Most patients use a once-weekly injection with a very fine needle. A daily tablet is available on request. Your clinician confirms which form is appropriate for you.
Mostly stomach-related: nausea, constipation or diarrhea, usually mildest when the dose is raised slowly. They are avoided in pregnancy and with a personal or family history of medullary thyroid cancer or MEN2.
You answer health questions online in about 5 minutes. A Vermont-licensed clinician reviews it by secure message, and if a GLP-1 is appropriate, a licensed pharmacy ships it in 2–3 business days.
Compounded semaglutide injections are $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. Your clinician, check-ins and messaging are included; shipping is free.
Compounded tirzepatide injections are $179 first month, then $299 every 4 weeks, charged once a clinician prescribes. Cancel anytime. Your clinician, check-ins and messaging are included; shipping is free.
Yes. Wegovy®, Zepbound® and Foundayo™ are FDA-approved for weight management, Ozempic® and Mounjaro® for type 2 diabetes. All are cash-pay: pens from $499 first month, daily pills from $299.
Vermont Medicaid covers GLP-1 agonists including Wegovy for clinically appropriate needs. Compounded GLP-1s are not covered. Pallas is cash-pay, so Medicaid rules do not apply.
Two cash-pay paths: stay on Wegovy® or Zepbound® from $499 first month, or a compounded plan from $139 first month if a licensed clinician finds it appropriate. Tell your clinician your current dose.
A decision for you and your clinician. Semaglutide costs less and has the longer track record; tirzepatide acts on two gut-hormone receptors instead of one. The comparison above covers the trials.
Pallas serves all of Vermont with one price for compounded semaglutide: $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. No video visit is required.
Rule changes affecting Vermont
- 2026-07-27 Correction — statute and rule citations updated on four state pages: Vermont now cites 18 V.S.A. § 9361(b) (previously a nonexistent § 3053a), Ohio cites Ohio Rev. Code § 4743.09 and OAC 4731-37-01 (previously the controlled-substances chapter 4731-11), Colorado cites C.R.S. § 12-240-107 (previously § 12-240-138, the professional-entities section), and Alabama cites Ala. Code §§ 34-24-701 through 34-24-707 (previously the repealed Admin. Code ch. 540-X-15). Regulatory substance is unchanged in all four.State statute and administrative-code databases; surfaced by our automated source check (PR #45).
From our state-by-state rules tracker. Get an email when a rule changes.
Pallas offers both FDA-approved and compounded medications. Compounded medications are not FDA-approved and are not generic versions of brand-name drugs. Eligibility and treatment are determined by a US-licensed clinician; results vary. Private pay only (no insurance). Operated by Brentmoor, Inc.